PT2706986E - Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos - Google Patents

Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos Download PDF

Info

Publication number
PT2706986E
PT2706986E PT127752830T PT12775283T PT2706986E PT 2706986 E PT2706986 E PT 2706986E PT 127752830 T PT127752830 T PT 127752830T PT 12775283 T PT12775283 T PT 12775283T PT 2706986 E PT2706986 E PT 2706986E
Authority
PT
Portugal
Prior art keywords
treatment
pharmaceutical composition
opioid dependence
resistant pharmaceutical
new abuse
Prior art date
Application number
PT127752830T
Other languages
English (en)
Inventor
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201161536180P priority Critical
Application filed by Orexo Ab filed Critical Orexo Ab
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2706986(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of PT2706986E publication Critical patent/PT2706986E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
PT127752830T 2011-09-19 2012-09-18 Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos PT2706986E (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201161536180P true 2011-09-19 2011-09-19

Publications (1)

Publication Number Publication Date
PT2706986E true PT2706986E (pt) 2015-07-07

Family

ID=47046639

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127752830T PT2706986E (pt) 2011-09-19 2012-09-18 Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos

Country Status (29)

Country Link
US (11) US8940330B2 (pt)
EP (2) EP2915525A1 (pt)
JP (2) JP6210988B2 (pt)
KR (1) KR20140075682A (pt)
CN (1) CN103813785B (pt)
AU (1) AU2012311293B2 (pt)
BR (1) BR112014006356A2 (pt)
CA (1) CA2834327C (pt)
CL (1) CL2014000575A1 (pt)
CO (1) CO6960541A2 (pt)
CY (1) CY1116270T1 (pt)
DK (1) DK2706986T3 (pt)
EA (1) EA029507B1 (pt)
ES (1) ES2538460T3 (pt)
HK (2) HK1193568A1 (pt)
HR (1) HRP20150369T1 (pt)
IL (1) IL230528A (pt)
ME (1) ME02153B (pt)
MX (1) MX361757B (pt)
NZ (2) NZ709502A (pt)
PE (1) PE20141198A1 (pt)
PL (1) PL2706986T3 (pt)
PT (1) PT2706986E (pt)
RS (1) RS53995B1 (pt)
SG (1) SG2014009401A (pt)
SI (1) SI2706986T1 (pt)
SM (1) SMT201500126B (pt)
WO (1) WO2013041851A1 (pt)
ZA (1) ZA201400501B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
US20140280531A1 (en) * 2013-03-13 2014-09-18 Xin Liu Object ranking and recommendations within a social network
US20160051536A1 (en) * 2013-04-08 2016-02-25 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
EP2886103A1 (en) * 2013-12-23 2015-06-24 Hexal AG Pharmaceutical orodispersible film comprising buprenorphine particles with a particular size
WO2018034920A1 (en) * 2016-08-17 2018-02-22 Insys Development Company, Inc. Liquid naloxone spray
CA2954370A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
CA3048360A1 (en) * 2016-12-26 2018-07-05 Shionogi & Co., Ltd. Production method for formulation having improved content uniformity
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab New pharmaceutical compositions
WO2019175100A1 (en) 2018-03-11 2019-09-19 Nanologica Ab Porous silica particles for use in compressed pharmaceutical dosage form

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
JPS5438168B2 (pt) 1974-09-24 1979-11-19
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4529583A (en) 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
FR2562313B1 (fr) 1984-04-03 1989-04-07 Cogema Procede de decontamination en uranium et en radium de solutions uraniferes acides par addition d'un sel d'aluminium
GB2162061B (en) 1984-05-03 1988-11-16 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4885173A (en) 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
SE8800080L (sv) 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US4981468A (en) 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5547878A (en) 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5856493A (en) 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
ES2168610T3 (es) 1996-03-12 2002-06-16 Alza Corp Composicion y forma galenica que contiene un antagonista opioide.
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB9710726D0 (en) 1997-05-23 1997-07-16 Nycomed Imaging As Compound
BRPI9802144B1 (pt) 1997-05-30 2017-03-28 Ezequiel Mayorga Jorge dispositivo osmótico multicapa aperfeiçoado
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100417490B1 (ko) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
AU4747401A (en) 2000-03-16 2001-09-24 Mclean Hospital Corp Compounds for the treatment of psychiatric or substance abuse disorders
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
CN1592609A (zh) 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
CA2512559A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
EP1750675B1 (en) * 2004-06-02 2008-10-29 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and salt thereof
US20060051413A1 (en) 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CA2599386A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
JP2007321063A (ja) * 2006-06-01 2007-12-13 Sumitomo Chemical Co Ltd 樹脂粒子の分離方法
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) * 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
MX2009000745A (es) 2006-07-21 2009-04-16 Biodelivery Sciences Int Inc Dispositivos de suministro transmucosa con admision mejorada.
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
PT2101740E (pt) 2006-12-04 2013-12-23 Orexo Ab Nova composição farmacêutica não susceptível de abuso que compreende opióides
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
JPWO2008111674A1 (ja) * 2007-03-15 2010-06-24 東洋紡績株式会社 口腔粘膜貼付ブプレノルフィン製剤の製造方法
GB2450117A (en) 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
JP2010043236A (ja) * 2008-07-17 2010-02-25 Sekisui Chem Co Ltd タンニン系接着剤、及びそれを用いた木質系複合材料
CN102421420A (zh) 2009-05-13 2012-04-18 蛋白传输解决方案有限责任公司 用于跨膜递送的药物系统
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
JP5371050B2 (ja) * 2009-11-06 2013-12-18 住友精化株式会社 ジボランの製造方法
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
PL3150199T3 (pl) 2012-05-02 2019-03-29 Orexo Ab Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu

Also Published As

Publication number Publication date
CO6960541A2 (es) 2014-05-30
US20170246161A1 (en) 2017-08-31
CN103813785A (zh) 2014-05-21
US9259421B2 (en) 2016-02-16
PL2706986T3 (pl) 2015-08-31
EA029507B1 (ru) 2018-04-30
ES2538460T3 (es) 2015-06-22
HK1210438A1 (zh) 2016-04-22
MX361757B (es) 2018-12-13
PE20141198A1 (es) 2014-10-05
CY1116270T1 (el) 2017-02-08
NZ618120A (en) 2015-10-30
EA201400246A1 (ru) 2014-05-30
SMT201500126B (it) 2015-07-09
CA2834327C (en) 2017-05-30
SI2706986T1 (sl) 2015-05-29
US20190054080A1 (en) 2019-02-21
WO2013041851A1 (en) 2013-03-28
CL2014000575A1 (es) 2014-08-01
US20150196492A1 (en) 2015-07-16
HRP20150369T1 (xx) 2015-05-08
AU2012311293A1 (en) 2013-05-02
IL230528D0 (en) 2014-03-31
BR112014006356A2 (pt) 2017-04-04
IL230528A (en) 2019-06-30
DK2706986T3 (en) 2015-06-01
US20140212496A1 (en) 2014-07-31
JP2014526496A (ja) 2014-10-06
SG2014009401A (en) 2014-05-29
MX2014002556A (es) 2014-10-06
KR20140075682A (ko) 2014-06-19
HK1193568A1 (en) 2015-09-25
CN103813785B (zh) 2017-02-15
ZA201400501B (en) 2017-06-28
RS53995B1 (en) 2015-10-30
EP2915525A1 (en) 2015-09-09
US8940330B2 (en) 2015-01-27
US20150297583A1 (en) 2015-10-22
US20180104235A1 (en) 2018-04-19
US9439900B2 (en) 2016-09-13
US20160375010A1 (en) 2016-12-29
ME02153B (me) 2015-10-20
EP2706986B1 (en) 2015-03-04
US20150238482A1 (en) 2015-08-27
CA2834327A1 (en) 2013-03-28
JP6210988B2 (ja) 2017-10-11
US20130071477A1 (en) 2013-03-21
US20140023704A1 (en) 2014-01-23
JP2017171687A (ja) 2017-09-28
EP2706986A1 (en) 2014-03-19
US20180042920A1 (en) 2018-02-15
AU2012311293B2 (en) 2014-02-20
NZ709502A (en) 2017-01-27

Similar Documents

Publication Publication Date Title
EP2542074A4 (en) Combination pharmaceutical agents as inhibitors of hcv replication
HK1197400A1 (zh) 治療 的化合物
EP2723384A4 (en) Treatment of proteinopathies
HK1206634A1 (en) Vehicles for controlled delivery of different pharmaceutical agents
GB201121070D0 (en) composition for delivery of biotherapeutics
EP2673286A4 (en) Therapeutic compounds
SG11201401851UA (en) Methods for drug delivery
DK2694038T3 (da) Farmaceutisk sammensætning
RU2016124562A (ru) Фармацевтическая композиция для лечения метаболического синдрома
PL2688556T3 (pl) Postaci dawkowania o kontrolowanym uwalnianiu
HU1000069A2 (en) New salts for the preparation of pharmaceutical composition
IL253221D0 (en) Pharmaceutical compositions comprising sorbitan esters
EP2670434A4 (en) Treatment of tauopathies
SG11201405243TA (en) Inhalable pharmaceutical compositions
HK1232158A1 (zh) 用於治療肝癌的藥物
IL228506A (en) Opioid receptor ligands and pharmaceutical compositions comprising them
EP2739144A4 (en) Compounds and therapeutic uses thereof
HK1206297A1 (zh) 用於聯合療法的藥物組合物
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
PL2750677T3 (pl) Inhibitory 3-monooksygenazy kinureninowej, kompozycje farmaceutyczne i sposoby ich stosowania
AP3544A (en) Compounds for the treatment of addiction
RS57101B1 (sr) Derivati tipa azaindazola ili diazaindazola kao lek
PL2773331T3 (pl) Preparaty do leczenia cukrzycy
ZA201306072B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
GB201113662D0 (en) Pharmaceutical compositions